NAGE Q4 2023 Earnings — Niagen Bioscience Inc Revenue & Financial Results | Market Cap Arena

NAGENiagen Bioscience Inc

$423M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M+1.0% YoY

Gross Profit

$13M61.0% margin

Operating Income

-$168,000-0.8% margin

Net Income

$114,0000.5% margin

EPS (Diluted)

$0.00

QoQ Revenue Growth

+8.7%

Cash Flow

Operating Cash Flow

$649,000

Free Cash Flow

$628,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$55M

Total Liabilities

$27M

Stockholders' Equity

$28M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$21M	+1.0%
Gross Profit	$13M	$12M	+7.7%
Operating Income	-$168,000	-$1M	+88.4%
Net Income	$114,000	-$1M	+108.0%